{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:19:16Z","timestamp":1770884356026,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03945-7","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T16:02:26Z","timestamp":1723651346000},"page":"882-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Finerenone and diabetic renal disease: a narrative review"],"prefix":"10.1007","volume":"86","author":[{"given":"Kirthika","family":"Venkatesan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mabel Mary James","family":"Cheryeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Tintu","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita Mariam","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikitha","family":"Ravisankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvathy","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishakh","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hridya","family":"Harimohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somy","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"6","key":"3945_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"R. Agarwal, G. Filippatos, B. Pitt, S.D. Anker, P. Rossing, A. Joseph, P. Kolkhof, C. Nowack, M. Gebel, L.M. Ruilope, G.L. Bakris; FIDELIO-DKD and FIGARO-DKD investigators, Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: he FIDELITY pooled analysis. Eur. Heart J. 43(6), 474\u2013484 (2022). https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur. Heart J."},{"key":"3945_CR2","unstructured":"Centers for Disease Control and Prevention (CDC). Diabetes and Chronic Kidney Disease. Retrieved from https:\/\/www.cdc.gov\/diabetes\/managing\/diabetes-kidney-disease.html#:~:text=CKD%20is%20common%20in%20people,diabetes%20can%20cause%20kidney%20disease (2023)"},{"issue":"3","key":"3945_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jdi.13355","volume":"12","author":"H Li","year":"2021","unstructured":"H. Li, W. Lu, A. Wang, H. Jiang, J. Lyu, Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. J. Diab. Investig. 12(3), 346\u2013356 (2021). https:\/\/doi.org\/10.1111\/jdi.13355","journal-title":"J. Diab. Investig."},{"issue":"1","key":"3945_CR4","first-page":"e12148","volume":"6","author":"A Makhlough","year":"2014","unstructured":"A. Makhlough, Z. Kashi, O. Akha, E. Zaboli, J. Yazdanicharati, Effect of spironolactone on diabetic nephropathy compared to the combination of spironolactone and losartan. Nephro-Urol. Monthly 6(1), e12148 (2014. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3968951\/","journal-title":"Nephro-Urol. Monthly"},{"key":"3945_CR5","doi-asserted-by":"publisher","first-page":"754239","DOI":"10.3389\/fphar.2021.754239","volume":"12","author":"D Kawanami","year":"2021","unstructured":"D. Kawanami, Y. Takashi, Y. Muta, N. Oda, D. Nagata, H. Takahashi, M. Tanabe, Mineralocorticoid receptor antagonists in diabetic kidney disease. Front. Pharmacol. 12, 754239 (2021. https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.754239\/full","journal-title":"Front. Pharmacol."},{"key":"3945_CR6","unstructured":"Bayer. Product monograph including patient medication information KERENDIA Finerenone tablets Tablets, 10 mg and 20 mg finerenone, Oral Aldosterone Antagonist. Retrieved from https:\/\/www.bayer.com\/sites\/default\/files\/kerendia-pm-en.pdf. (2022)."},{"issue":"11","key":"3945_CR7","doi-asserted-by":"publisher","first-page":"e0259485","DOI":"10.1371\/journal.pone.0259485","volume":"16","author":"T Iwahana","year":"2021","unstructured":"T. Iwahana, Y. Saito, S. Okada, H. Kato, R. Ono, Y. Kobayashi, Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study. PLOS ONE 16(11), e0259485 (2021). https:\/\/doi.org\/10.1371\/journal.pone.0259485","journal-title":"PLOS ONE"},{"issue":"2","key":"3945_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"R. Agarwal, P. Kolkhof, G. Bakris, J. Bauersachs, H. Haller, T. Wada, F. Zannad, Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 42(2), 152\u2013161 (2021). https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur. Heart J."},{"issue":"7","key":"3945_CR9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/dom.14696","volume":"24","author":"RA DeFronzo","year":"2022","unstructured":"R.A. DeFronzo, G.L. Bakris, Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diab. Obes. Metab. 24(7), 1197\u20131205 (2022). https:\/\/doi.org\/10.1111\/dom.14696","journal-title":"Diab. Obes. Metab."},{"issue":"3","key":"3945_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000515622","volume":"52","author":"M Epstein","year":"2021","unstructured":"M. Epstein, Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: From Hans Selye to the present. Am. J. Nephrol. 52(3), 209\u2013216 (2021). https:\/\/doi.org\/10.1159\/000515622","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"3945_CR11","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"P. Kolkhof, L. B\u00e4rfacker, 30 Years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J. Endocrinol. 234(1), T125\u2013T140 (2017). https:\/\/doi.org\/10.1530\/JOE-16-0600","journal-title":"J. Endocrinol."},{"issue":"3","key":"3945_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","volume":"24","author":"A Chaudhuri","year":"2022","unstructured":"A. Chaudhuri, H. Ghanim, P. Arora, Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diab. Obes. Metab. 24(3), 365\u2013376 (2022). https:\/\/doi.org\/10.1111\/dom.14601","journal-title":"Diab. Obes. Metab."},{"issue":"2","key":"3945_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"P Kolkhof","year":"2012","unstructured":"P. Kolkhof, S.A. Borden, Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol. Cell. Endocrinol. 350(2), 310\u2013317 (2012). https:\/\/doi.org\/10.1016\/j.mce.2011.06.025","journal-title":"Mol. Cell. Endocrinol."},{"issue":"36","key":"3945_CR14","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"L. Amazit, F.L. Billan, P. Kolkhof et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J. Biol. Chem. 290(36), 21876\u201321889 (2015). https:\/\/doi.org\/10.1074\/jbc.M115.657957","journal-title":"J. Biol. Chem."},{"issue":"23","key":"3945_CR15","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"G.L. Bakris, R. Agarwal, S.D. Anker, B. Pitt, L.M. Ruilope, P. Rossing, G. Filippatos, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383(23), 2219\u20132229 (2020). https:\/\/doi.org\/10.1056\/nejmoa2025845","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"3945_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"R. Agarwal, A. Joseph, S.D. Anker, G. Filippatos, P. Rossing, L.M. Ruilope, B. Pitt, P. Kolkhof, C. Scott, R. Lawatscheck, D.J. Wilson, G.L. Bakris; FIDELIO-DKD Investigators, Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J. Am. Soc. Nephrology: JASN 33(1), 225\u2013237 (2022). https:\/\/doi.org\/10.1681\/ASN.2021070942","journal-title":"J. Am. Soc. Nephrology: JASN"},{"issue":"3","key":"3945_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40262-021-01083-1","volume":"61","author":"SC Goulooze","year":"2022","unstructured":"S.C. Goulooze, N. Snelder, A. Seelmann, A. Horvat-Broecker, M. Brinker, A. Joseph, D. Garmann, J. Lippert, T. Eissing, Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria. Clin. Pharmacokinetics 61(3), 451\u2013462 (2022). https:\/\/doi.org\/10.1007\/s40262-021-01083-1","journal-title":"Clin. Pharmacokinetics"},{"key":"3945_CR18","doi-asserted-by":"publisher","first-page":"1040040","DOI":"10.3389\/fendo.2022.1040040","volume":"13","author":"ADS Chaves","year":"2022","unstructured":"A.D.S. Chaves, N.S. Magalh\u00e3es, D.B.R. Insuela, P.M.R.E. Silva, M.A. Martins, V.F. Carvalho, Effect of the renin-angiotensin system on the exacerbation of adrenal glucocorticoid steroidogenesis in diabetic mice: Role of angiotensin-II type 2 receptor. Front. Endocrinol. 13, 1040040 (2022. https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1040040\/full","journal-title":"Front. Endocrinol."},{"issue":"9","key":"3945_CR19","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","volume":"79","author":"JM Brown","year":"2022","unstructured":"J.M. Brown, M.O. Wijkman, B.L. Claggett, A.M. Shah, C.M. Ballantyne, J. Coresh, S.D. Solomon, Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study. Hypertension 79(9), 1984\u20131993 (2022. https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/HYPERTENSIONAHA.122.19134","journal-title":"Hypertension"},{"issue":"1","key":"3945_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"P. Kolkhof, M. Delbeck, A. Kretschmer, W. Steinke, E. Hartmann, L. B\u00e4rfacker, S. Sch\u00e4fer, Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovascular Pharmacol. 64(1), 69\u201378 (2014. https:\/\/journals.lww.com\/cardiovascularpharm\/FullText\/2014\/07000\/Finerenone,_a_Novel_Selective_Nonsteroidal.11.aspx","journal-title":"J. Cardiovascular Pharmacol."},{"key":"3945_CR21","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"J. Barrera-Chimal, G.R. Estrela, S.M. Lechner, S. Giraud, S. El Moghrabi, S. Kaaki, F. Jaisser, The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344\u20131355 (2018. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0085253818300607","journal-title":"Kidney Int."},{"issue":"8","key":"3945_CR22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"P. Kolkhof, E. Hartmann, A. Freyberger, M. Pavkovic, I. Mathar, P. Sandner, F. Eitner, Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642\u2013652 (2021. https:\/\/karger.com\/ajn\/article\/52\/8\/642\/827352","journal-title":"Am. J. Nephrol."},{"issue":"24","key":"3945_CR23","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"B. Pitt, G. Filippatos, R. Agarwal, S.D. Anker, G.L. Bakris, P. Rossing, L.M. Ruilope, Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385(24), 2252\u20132263 (2021). https:\/\/doi.org\/10.1056\/nejmoa2110956","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"3945_CR24","doi-asserted-by":"publisher","first-page":"102638","DOI":"10.1016\/j.dsx.2022.102638","volume":"16","author":"AK Singh","year":"2022","unstructured":"A.K. Singh, A. Singh, R. Singh, A. Misra, Finerenone in diabetic kidney disease: A systematic review and critical appraisal. Diab. Metab. Syndr. 16(10), 102638 (2022). https:\/\/doi.org\/10.1016\/j.dsx.2022.102638","journal-title":"Diab. Metab. Syndr."},{"issue":"6","key":"3945_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/circulationaha.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"G. Filippatos, S.D. Anker, R. Agarwal, L.M. Ruilope, P. Rossing, G.L. Bakris, C. Tasto, A. Joseph, P. Kolkhof, A. Lage, B. Pitt; FIGARO-DKD Investigators, Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial. Circulation 145(6), 437\u2013447 (2022). https:\/\/doi.org\/10.1161\/circulationaha.121.057983","journal-title":"Circulation"},{"issue":"4","key":"3945_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/ndt\/gfac198","volume":"38","author":"JB Green","year":"2023","unstructured":"J.B. Green, A.K. Mottl, G. Bakris, H.J.L. Heerspink, J.F.E. Mann, J.B. McGill, M. Nangaku, P. Rossing, C. Scott, A. Gay, R. Agarwal, Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol. Dialysis Transpl. 38(4), 894\u2013903 (2023). https:\/\/doi.org\/10.1093\/ndt\/gfac198","journal-title":"Nephrol. Dialysis Transpl."},{"key":"3945_CR27","unstructured":"Kerendia prices, coupons, Copay & Patient Assistance. Drugs.com. (n.d.). https:\/\/www.drugs.com\/price-guide\/kerendia"},{"key":"3945_CR28","unstructured":"Cadth reimbursement recommendation Finerenone (Kerendia). https:\/\/www.cadth.ca\/sites\/default\/files"},{"issue":"4","key":"3945_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/dc21-1944","volume":"45","author":"P Rossing","year":"2022","unstructured":"P. Rossing, E. Burgess, R. Agarwal, S.D. Anker, G. Filippatos, B. Pitt et al. Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: An analysis from the FIDELIO-DKD study. Diab. Care 45(4), 888\u2013897 (2022). https:\/\/doi.org\/10.2337\/dc21-1944","journal-title":"Diab. Care"},{"issue":"22","key":"3945_CR30","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.2169\/internalmedicine.49.4055","volume":"49","author":"C Ibuki","year":"2010","unstructured":"C. Ibuki, H. Kawamata, Y. Seino, K. Mizuno, Successful blood pressure control with additive administration of eplerenone, an aldosterone receptor blocker, in a patient with bilateral renovascular hypertension treated with angioplasty. Intern. Med. 49(22), 2455\u20132459 (2010). https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/49\/22\/49_22_2455\/_article\/-char\/ja\/","journal-title":"Intern. Med."},{"issue":"6","key":"3945_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/jcdd10060236","volume":"10","author":"F Piccirillo","year":"2023","unstructured":"F. Piccirillo, P. Liporace, A. Nusca, V. Nafisio, A. Corlian\u00f2, F. Magar\u00f2, F. Grigioni, Effects of finerenone on cardiovascular and chronic kidney diseases: A new weapon against cardiorenal morbidity and mortality\u2014a comprehensive review. J. Cardiovascular Dev. Dis. 10(6), 236 (2023). https:\/\/www.mdpi.com\/2308-3425\/10\/6\/236","journal-title":"J. Cardiovascular Dev. Dis."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03945-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T03:05:20Z","timestamp":1731467120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03945-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3945"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03945-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}